Filing Flows › Neuroone Medical Technologies (NMTC) › R&D spending
Neuroone Medical Technologies (NMTC) R&D spending by quarter
Neuroone Medical Technologies' R&D spending was $1.4M in Q3 FY26 (third quarter fiscal 2026), -3% from Q2 FY26. Over the last 7 quarters it ranged from $1.1M (Q4 FY24) to $1.5M (Q2 FY25).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $1.4M | -3% | +21% |
| Q2 FY26 | $1.5M | +6% | -3% |
| Q1 FY26 | $1.4M | +24% | — |
| Q4 FY25 | $1.1M | -5% | +0.4% |
| Q3 FY25 | $1.2M | -22% | — |
| Q2 FY25 | $1.5M | +36% | — |
| Q4 FY24 | $1.1M | — | — |
Q3 FY26 at a glance
Neuroone Medical Technologies, Q3 FY26: revenue $2.0M (+16% year over year), operating margin -122.9%, net loss $2.0M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neuroone Medical Technologies' R&D spending?
Neuroone Medical Technologies' R&D spending was $1.4M in Q3 FY26 (third quarter fiscal 2026), -3% from Q2 FY26.
How has Neuroone Medical Technologies' R&D spending changed?
Over the last 7 quarters it ranged from $1.1M (Q4 FY24) to $1.5M (Q2 FY25).
Q3 FY26 results → · How Neuroone Medical Technologies makes money →